SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma announces US FDA filing acceptance of New Drug Application for Deuruxolitinib06-10-2023
06-10-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Acquisition
Acquisition and Update on Acquisition05-10-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Acquisition
Intimation related to acquisition of balance stake in a subsidiary company.28-09-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma Canada launches Winlevi a novel topical treatment for acne.27-09-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Closure of Trading Window
Intimation of closure of trading window25-09-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
As per the attached pdf.25-09-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
As attached in the pdf.20-09-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor Meeting18-09-2023
Sun Pharma inks agreement with US-based Pharmazz on cerebral ischemic stroke drug
Sun Pharma has been granted rights for marketing Sovateltide in India under the brand name Tyvalzi14-09-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India14-09-2023